Survey Says Epocrates Enjoys iPhone Success


By Neil Versel

Sept. 16, 2008 | If the iPhone is the killer app that pushes thousands of physicians to adopt health-IT (see “iPhone Will Change Health-IT, Says Datamonitor”), then the Epocrates Rx drug and formulary reference might be the software equivalent. At least that’s what San Mateo, Calif.-based Epocrates is claiming, based on the results of a customer survey.

Some 25,000 U.S. physicians were among the 125,000 users who downloaded the iPhone version of Epocrates Rx in the first month of availability, Epocrates says. And 72 percent of doctors said the availability of the Epocrates software was “important” or “very important” in their decision to buy an iPhone or the related iPod Touch, according to a survey released Monday.

The results may not be too surprising, based on the longstanding popularity of Epocrates reference tools with clinicians. But the company also reports heavy consumer interest in the new product; perhaps 40,000 non-health care professionals downloaded the iPhone software in the first few weeks after its June release.

“We’ve had many more consumers downloading our iPhone application than our other versions,” says Michelle Snyder, vice president of marketing for Epocrates. Snyder attributes this mostly to the high visibility the product has had in the Apple App Store, helping to draw in customers who otherwise would not be aware of Epocrates.

Epocrates was among the first companies to develop third-party applications for the hot-selling iPhone. (See “Epocrates Coming to an iPhone Near You” and “iPhone Is the Apple of Epocrates’ Eye.”) Epocrates surveyed 303 physicians and 304 consumers in August. All downloaded Epocrates Rx for iPhone or iPod Touch during the first week of availability in June, the company says.

Consumers do seem to like having mobile access to health information. According to the survey, 35 percent of consumers with Epocrates Rx for the iPhone report using the software several times a week, and another 54 percent turn to it once a week. Furthermore, nearly two-thirds of consumers have recommended Epocrates to their care providers or plan on doing so in the future.

“Consumers are better monitoring their own care and also managing the care of others,” Snyder says. Indeed, two-thirds of consumers got the Epocrates software to monitor personal conditions. About 23 percent say they were taking care of a relative or friend.

Typical of consumer comments was: “My roommate had a bad allergic reaction to a drug. We contacted her doctor with Epocrates’ information and he changed the medicine.”

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Digital End-To-End for Pharma
Sponsored by SAIC

Given the rapidly changing pharmaceutical industry landscape, traditional methods alone of identifying, retrieving, and analyzing the private and publicly available information no longer suffice. How can Pharma effectively harness the immense amounts of data from an ever-growing number of internal and external sources?

The Digital End-to-End white paper discusses some of the ways that Pharma can harness the power of the data to pursue novel products that are profitable, safe, and have proven value to one or more patient populations.



Adobe® LiveCycle® ES
Deploying Adobe Technology to Automate Electronic Submissions
Sponsored by Adobe
Discover how to:
  • Help reduce the cost of bringing products to market
  • Improve document collaboration across your organization
  • Satisfy global regulatory requirements, stockholder expectations, and customer demands
  • Improve data capture, information assurance, document output, process management, and content services
  • Gain a competitive advantage, get immediate ROI


Interoperability and Architecture for the Life Sciences Industry
What it will take to gain industry consensus on interchange standards, and what organizations can do today to optimize their own information architectures
Sponsored by SAS
Information technology is finally up to the task of cost-effective clinical research. But there are still some significant barriers to gaining all the benefits of this technology, in particular, interoperability. This white paper explores the need for a consistent industry architecture that allows life sciences firms to connect their enterprises and benefit from unified data integration, process consistency and rapid communication of meaningful drug findings.


Life Science Webcasts & Podcasts

Medidata Solutions

Rising Clinical Trial Delays and Costs - Addressing the Cause, Not the Symptoms

Protocol complexity is taking a toll on clinical study speed and efficiency: increasingly complicated and ambitious protocols are not only burdening sites and study volunteers but are also prolonging trials and increasing expenses. In response, sponsors have turned to global study placement, restructured site relationships and new site management practices, but the problem remains.

This podcast will discuss:

  • Why these responses address only the symptoms, not the underlying cause, of rising clinical trial delays and costs.
  • Results of a recent joint Tufts University / Medidata Solutions study.
  • New metrics benchmarking protocol design trends.
  • Systematic protocol design improvements and why they are essential to clinical trial performance excellence.

Speakers: Ken Getz, Senior Research Fellow at the Tufts Center for the Study of Drug Development, and Ed Seguine, General Manager, Trial Planning Solutions at Medidata.

Download Now



More Podcasts

Job Openings

Manager, Scientific Computing & Programming
Lead SAIC-Frederick, Inc.’s Bioinformatics & Analysis Group in developing & maintaining informatics pipelines for generation/analysis of dense genotyping & next-generation sequencing data. Required: MS or equiv. 5 yrs related experience. Knowledge of programming/software development, high performance computing, bioinformatics, project management. Visit www.saic-frederick.com - #130019.

Related Resources & Products

Combination Drug/Diagnostic Products: Pathways to R&D and Commercial Success
Combination Drug/Diagnostic Products: Pathways to R&D; and Commercial Success
Senior Management_Disabler or Enabler of Alliance Success
The US Drug Approval Trends and Yearbook 2008/2009



For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to [email protected].